MaxCyte, Inc. Proceeds from Common Stock Issued
MaxCyte, Inc. (MXCT) reported Proceeds from Common Stock Issued of $1.60 million for the 6-month period ending 2023-06-30, per its 10-Q filed 2023-08-09.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2023-08-09
- MaxCyte, Inc. proceeds from issuance of common stock for the quarter ending 2021-03-31 was 40.20M GBP.
GBP
| Period end | Proceeds from Issuance of Common Stock 1 month | Proceeds from Issuance of Common Stock 3 month |
|---|---|---|
| 2021-03-31 | 40.20M GBP 10-Q · filed 2021-11-10 | |
| 2021-02-28 | 40.20M GBP 10-Q · filed 2022-11-09 | |
| 2019-03-31 | 10.00M GBP 10-K · filed 2022-03-22 |
USD
| Period end | Proceeds from Issuance of Common Stock 1 month | Proceeds from Issuance of Common Stock 3 month | Proceeds from Issuance of Common Stock 3 month as first filed | Proceeds from Issuance of Common Stock 6 month | Proceeds from Issuance of Common Stock 9 month | Proceeds from Issuance of Common Stock 12 month |
|---|---|---|---|---|---|---|
| 2023-06-30 | $100.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $1.60M 10-Q · filed 2023-08-09 | ||||
| 2023-03-31 | $1.50M 10-Q · filed 2023-05-10 | |||||
| 2022-12-31 | $2.90M 10-Q · filed 2023-05-10 | |||||
| 2021-12-31 | -$184.27M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $0.00 derived: sum of 2 quarters · filed 2023-03-15 | $0.00 derived: sum of 3 quarters · filed 2023-03-15 | $51.81M 10-K · filed 2023-03-15 | ||
| 2021-09-30 | $184.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $184.27M derived: sum of 2 quarters · filed 2022-11-09 | $236.08M 10-Q · filed 2022-11-09 | $236.08M derived: sum of 4 quarters · filed 2022-11-09 | ||
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $51.81M 10-Q · filed 2022-08-10 | $51.81M derived: sum of 3 quarters · filed 2022-08-10 | $51.81M derived: sum of 4 quarters · filed 2022-08-10 | ||
| 2021-03-31 | $51.81M 10-Q · filed 2022-05-09 | $55.30M 10-Q · filed 2021-09-13 | $51.81M derived: sum of 2 quarters · filed 2022-05-09 | $51.81M derived: sum of 3 quarters · filed 2022-05-09 | ||
| 2021-02-28 | $55.30M 10-Q · filed 2022-11-09 | |||||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22 | $0.00 derived: sum of 2 quarters · filed 2022-03-22 | $28.57M 10-K · filed 2022-03-22 | |||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $28.57M 10-Q · filed 2021-11-10 | ||||
| 2020-06-30 | $28.57M 10-Q · filed 2021-09-13 | |||||
| 2019-12-31 | $12.33M 10-K · filed 2022-03-22 | |||||
| 2019-03-31 | $13.30M 10-K · filed 2022-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |